Hemodynamic and Renal Effects of ProANF_31–67 in Hypertensive Rats

Abstract

It has been demonstrated previously that the atrial natriuretic factor prohormone fragment 31-67 (ProANF31-67) circulates in animals and possesses natriuretic and vasodilating actions. Although the plasma levels of the peptide are reportedly elevated in patients with high blood pressure, its role and actions in hypertension are unknown. In the present study, synthetic human ProANF31-67 was infused intravenously at doses of 0, 10, 30, and 100 ng/kg/min into respective groups of anesthetized normotensive and spontaneously hypertensive rats. Mean arterial pressure (MAP), urine flow rate (UV), and sodium excretion (UNaV) were measured during two consecutive 30-min periods. In both strains of rats, reductions in MAP with ProANF31-67 were similar in magnitude and dose-related. Sodium excretion responses to the peptide infusions also were remarkably similar in both normotensive and hypertensive rats, and the responses demonstrated 3- to 5-fold (P < 0.05) increments compared to control at the doses of 10 and 30 ng/kg/min. However, in the two strains of rats, attenuation of natriuresis occurred with the highest infusion dose of 100 ng/kg/min and was probably related to the large decreases in MAP of 17-23 mmHg at this dose of the peptide. The present results indicate the ProANF31-67 has important hemodynamic and renal effects in hypertension and may represent one compensatory mechanism involved in this disease.

Primary Malignant Tumors of the Heart: Four Cardiovascular Hormones Decrease the Number and DNA Synthesis of Human Angiosarcoma Cells

“…The cardiovascular hormones do not produce myelosuppression or cardiomyopathy [19,20,21]. These peptide hormones which normally circulate in the human body [26,27,28,29,30,31] have no cytoxic effects on normal cells [4] and only one known side effect [12,13,14,15,16,17,18,19,20,21,22,23,24]. This side effect, i.e.…”

“…hypotension, has only been observed with ANP and BNP and never with vessel dilator, LANP or kaliuretic peptide, i.e. the cardiovascular hormones with the best safety profile [12,13,14,15,16,17,18,19,20,21,22,23,24]. …”

“…Within the 126-aa ANP prohormone are four peptide hormones whose main known biologic properties are blood pressure regulation and maintenance of plasma volume in animals [12,13,14,15,16,17,18] and humans [19,20,21]. These peptide hormones are LANP, vessel dilator, kaliuretic peptide and ANP [11, 22].…”

Cardiac hormones for the treatment of cancer

“…1). The main physiological properties of these four peptide hormones after their release from the heart are blood pressure regulation and the maintenance of plasma volume in animals (Vesely et al 1987, Martin et al 1990, Gunning et al 1992, Benjamin & Peterson 1995, Zeidel 1995, Villarreal et al 1999, Dietz et al 2001 and humans (Vesely et al 1994a(Vesely et al ,b, 1998. The cardiac hormones, synthesized in the atrium of the heart, are long-acting natriuretic peptide (LANP) that consists of the first 30 a.a. from the N-terminal end of the ANP prohormone; vessel dilator, a.a. 31-67; kaliuretic peptide, a.a. 79-98; and ANP, a.a. 99-126 of the 126 a.a. prohormone (Vesely 1992(Vesely , 2002; Fig.…”

Urodilatin: A better natriuretic peptide?

“…1). Within the 126 a.a. prohormone in the heart are four peptide hormones whose main biologic properties are blood pressure regulation and maintenance of plasma volume in animals [5][6][7][8][9][10][11] and humans [12][13][14][15][16]. These peptide hormones, numbered by their a.a. sequences beginning at the N-terminal end of the ANP prohormone, consist of the first 30 a.a. of the prohormone-that is, long acting natriuretic peptide (LANP), vessel dilator (a.a. 31-67), kaliuretic peptide (a.a. 79-98), and ANP (a.a. 99-126) [2,3].…”